已上市人乳头瘤病毒疫苗的概况及其在国内的临床研究进展

Commercial human papilloma virus vaccine and its clinical trial progress in China

宫颈癌是女性常见的恶性肿瘤,人乳头瘤病毒(human papilloma virus,HPV)是诱发该病的主要病原。HPV疫苗是全球首个预防癌症的疫苗,已在多个国家广泛应用。目前成功上市的宫颈癌疫苗有默沙东公司研发的4价和9价Gardasil及葛兰素史克公司(GSK)研发的Cervarix;在我国,HPV疫苗于2016年7月上市。本文就上述疫苗的基本情况、安全性、保护效果及免疫原性作一综述,并对HPV疫苗在国内的临床研究现状进行简介。

Cervical cancer is a common malignancy in gynecology, of which the major pathogen is human papilloma virus（HPV）. HPV vaccine, the first vaccine against cancers in the world, has been widely used in many countries. There are 3kinds of commercial vaccines, i. e. Cervarix produced by GSK as well as Gardasil 4 and Gardasil 9 produced by Merck Co. However, in China, HPV vaccine will be enter market in July 2016. This paper reviews the basic situation, safety,protective effect, immunogenicity and the current situation of study on HPV vaccine in China.